Standard
Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial. / Ashina, Messoud; Goadsby, Peter J.; Reuter, Uwe; Silberstein, Stephen; Dodick, David W.; Xue, Fei; Zhang, Feng; Paiva Da Silva Lima, Gabriel; Cheng, Sunfa; Mikol, Daniel D.
In:
European Journal of Neurology, Vol. 28, No. 5, 01.05.2021, p. 1716-1725.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Ashina, M, Goadsby, PJ, Reuter, U, Silberstein, S, Dodick, DW, Xue, F, Zhang, F, Paiva Da Silva Lima, G, Cheng, S & Mikol, DD 2021, '
Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial',
European Journal of Neurology, vol. 28, no. 5, pp. 1716-1725.
https://doi.org/10.1111/ene.14715
APA
Ashina, M., Goadsby, P. J., Reuter, U., Silberstein, S., Dodick, D. W., Xue, F., Zhang, F., Paiva Da Silva Lima, G., Cheng, S., & Mikol, D. D. (2021).
Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial.
European Journal of Neurology,
28(5), 1716-1725.
https://doi.org/10.1111/ene.14715
Vancouver
Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F et al.
Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial.
European Journal of Neurology. 2021 May 1;28(5):1716-1725.
https://doi.org/10.1111/ene.14715
Author
Ashina, Messoud ; Goadsby, Peter J. ; Reuter, Uwe ; Silberstein, Stephen ; Dodick, David W. ; Xue, Fei ; Zhang, Feng ; Paiva Da Silva Lima, Gabriel ; Cheng, Sunfa ; Mikol, Daniel D. / Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial. In: European Journal of Neurology. 2021 ; Vol. 28, No. 5. pp. 1716-1725.
Bibtex
@article{de206c7096084320bb102c59ff7123ff,
title = "Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial",
author = "Messoud Ashina and Goadsby, {Peter J.} and Uwe Reuter and Stephen Silberstein and Dodick, {David W.} and Fei Xue and Feng Zhang and {Paiva Da Silva Lima}, Gabriel and Sunfa Cheng and Mikol, {Daniel D.}",
year = "2021",
month = may,
day = "1",
doi = "10.1111/ene.14715",
language = "English",
volume = "28",
pages = "1716--1725",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell",
number = "5",
}
RIS
TY - JOUR
T1 - Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
AU - Ashina, Messoud
AU - Goadsby, Peter J.
AU - Reuter, Uwe
AU - Silberstein, Stephen
AU - Dodick, David W.
AU - Xue, Fei
AU - Zhang, Feng
AU - Paiva Da Silva Lima, Gabriel
AU - Cheng, Sunfa
AU - Mikol, Daniel D.
PY - 2021/5/1
Y1 - 2021/5/1
U2 - 10.1111/ene.14715
DO - 10.1111/ene.14715
M3 - Journal article
C2 - 33400330
VL - 28
SP - 1716
EP - 1725
JO - European Journal of Neurology
JF - European Journal of Neurology
SN - 1351-5101
IS - 5
ER -
